Bacopa Monnieri
Cognitive & NootropicLast reviewed: May 26, 2026
Also Known As: Brahmi, water hyssop, thyme-leaved gratiola, herb of grace, BM, bacosides
Supplement Class: Ayurvedic adaptogenic herb / cumulative nootropic (bacoside-standardized triterpenoid saponin extract)
Evidence Tier: Strong — Kongkeaw 2014 meta-analysis of 9 RCTs; multiple independent 12-week RCTs (Stough 2001, Roodenrys 2002, Calabrese 2008, Stough 2008) consistently demonstrating chronic memory and anxiolytic effects; among the better-supported herbal nootropics in the Western literature
What is Bacopa monnieri?
Bacopa monnieri is a creeping aquatic herb native to South Asian wetlands and a cornerstone of Ayurvedic medicine, where it has been used for memory and cognitive support for centuries. Its active compounds — bacosides A and B (triterpenoid saponins) — drive the modern nootropic case. Unlike most cognitive supplements that produce acute, same-day effects, Bacopa works through structural neural remodeling: dendritic branching, synaptic protein synthesis, acetylcholinesterase inhibition, and antioxidant neuroprotection. The cognitive benefits are cumulative and build over 8–12 weeks of consistent use. It is one of the better-studied herbal nootropics in Western science — multiple independent 12-week RCTs (Stough, Roodenrys, Calabrese) and the Kongkeaw 2014 meta-analysis consistently show improvements in delayed recall and information retention in healthy adults. It pairs naturally with cognitive peptides that work on a different timescale: peptides handle the acute focus and resilience; Bacopa handles the chronic memory consolidation.
Reported benefits:
- Improved delayed recall and memory consolidation (most-replicated RCT finding)
- Reduced rate of forgetting newly learned material (Roodenrys 2002)
- Anxiety and depression reduction in older adults (Calabrese 2008)
- Speed of information processing and rapid visual information processing (Stough trials)
- Antioxidant neuroprotection in hippocampal neurons
- Mild acetylcholinesterase inhibition (same mechanism class as donepezil, at lower magnitude)
- Serotonergic modulation and cortisol response shaping under chronic stress
Common dose: 300 mg once daily of an extract standardized to 50–55% bacosides (the dose used in nearly all positive RCTs). Split dosing (150 mg twice daily with meals) is an option for GI tolerability. Higher doses (600 mg/day) are tolerated but don't clearly accelerate the 8–12 week timeline.
Where to buy: Available over-the-counter from most supplement retailers. Quality varies — particularly around bacoside standardization. Review the quality-markers checklist in the Where to Buy section below before purchasing.
Shop Bacopa Monnieri on Amazon →How does Bacopa monnieri work?
Bacopa works through several parallel mechanisms — most importantly, bacoside-driven dendritic branching and synaptic remodeling in hippocampal neurons. This is structural rather than receptor-level, which is why the cognitive effects build over weeks rather than appearing acutely. The acetylcholinesterase-inhibition and serotonergic-modulation arms add layered support for memory and mood.
- Bacoside-driven synaptic remodeling. Bacosides A and B (the dominant active triterpenoid saponins) enhance kinase activity, neuronal protein synthesis, and dendritic branching in hippocampal neurons. This produces the structural cognitive remodeling that underlies Bacopa's chronic memory effect — and explains why a single dose does nothing measurable.
- Acetylcholinesterase inhibition. Bacopa inhibits acetylcholinesterase — the enzyme that breaks down acetylcholine — raising cholinergic tone in cortex and hippocampus. This is the same mechanism class as donepezil and rivastigmine (Alzheimer's medications), at a much milder magnitude. The cholinergic arm contributes to attention and short-term memory effects.
- Antioxidant neuroprotection. Bacosides are potent free-radical scavengers in brain tissue and upregulate endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase). This protects hippocampal neurons from oxidative damage — a mechanism implicated in cognitive aging and neurodegeneration.
- Serotonergic and HPA-axis modulation. Bacopa enhances serotonergic neurotransmission and modulates cortisol response under stress — the mechanistic basis for its anxiolytic effects documented in Calabrese 2008 and other chronic-use trials. This is one reason Bacopa differs from stimulant nootropics: it tends to reduce rather than increase anxiety with chronic use.
- Cerebral blood flow. Animal and limited human data suggest Bacopa increases cerebral blood flow, potentially via nitric-oxide-mediated vasodilation. The clinical relevance is unclear, but it's a recurring mechanistic finding in the preclinical literature.
What does Bacopa monnieri actually do?
Bacopa has one of the deeper Western RCT bases of any traditional herbal nootropic. The strongest evidence is for chronic memory consolidation and information retention in healthy adults; secondary evidence covers anxiety reduction and processing speed. Acute effects are essentially absent — this is a chronic-use supplement.
- Memory consolidation and information retention (Strong). Multiple 12-week RCTs (Stough 2001, Roodenrys 2002, Calabrese 2008, Stough 2008) consistently show Bacopa improves delayed recall and reduces the rate of forgetting newly learned material. The Kongkeaw 2014 meta-analysis (9 RCTs, n=437) confirms the effect across pooled data. The cognitive gain is specifically retention-oriented; working memory and acute attention effects are smaller.
- Processing speed and attention (Moderate). The Stough group's chronic Bacopa trials document significant improvements in speed of information processing and rapid visual information processing after 90 days. Effect sizes are moderate; the directional signal across independent trials is consistent.
- Anxiety and mood (Moderate). Calabrese 2008 documented significant reductions in anxiety and depression scale scores in older adults at 12 weeks. Stough 2008 found reductions in state anxiety. The anxiolytic effect is chronic and gradual — not acute like benzodiazepines or Selank — but real in the RCT literature.
- ADHD and pediatric cognition (Emerging). Indian RCTs in children with ADHD suggest cognitive improvements, but the evidence is limited to a small research base and hasn't been replicated outside India. Treat as plausible but not established.
- Neuroprotection in aging (Mechanism-based). Strong preclinical evidence for antioxidant neuroprotection and reduced beta-amyloid burden in animal models. Human trials in MCI and Alzheimer's are limited; the population-specific clinical case is weaker than the broader cognitive-enhancement case in healthy adults.
How is Bacopa monnieri dosed?
Bacopa dosing is built around standardized extracts — not raw powder, which is too variable. The published RCT dose is 300 mg/day of an extract standardized to 50–55% bacosides; a few trials use up to 600 mg/day. Higher doses don't appear to accelerate the timeline — the 8–12 week onset is structural and dose-insensitive within the studied range.
- Standard daily dose. 300 mg once daily of a 50–55% bacoside-standardized extract — the dose used in nearly all positive RCTs (Stough 2001, Roodenrys 2002, Calabrese 2008, Stough 2008).
- Split dosing for GI tolerability. 150 mg twice daily with meals — same total dose, smoother GI experience for sensitive users.
- Higher dose (600 mg). 300 mg twice daily — used in some trials and tolerated, but no clear evidence of larger cognitive effect. Reserve for users who plateau on 300 mg after 12 weeks.
- Branded-extract equivalence. CDRI-08 and BacoMind: 320 mg/day is the manufacturer-recommended dose for both — matched to RCTs using those specific extracts.
Timeline: nothing measurable in the first 2–4 weeks; subtle improvements emerge at 5–6 weeks; the clinical-trial effect size is reached at 8–12 weeks. If you're looking for an acute focus or attention lift, Bacopa is the wrong supplement — Alpha-GPC, caffeine + L-theanine, or a racetam stack is what you want for same-day effects.
Label math. “500 mg Bacopa monnieri (50% bacosides)” means 250 mg of actual bacoside content — within RCT range. “500 mg Bacopa monnieri whole herb” with no bacoside percentage is unstandardized and may contain anywhere from 5–20% bacosides. Always buy a standardized extract with a stated bacoside percentage.
How to take Bacopa monnieri
Bacopa is taken orally, almost always as a capsule of standardized extract. Raw powder is available but bitter and inconsistently dosed; tinctures exist but offer no clear advantage. The points below cover the practical details that experienced users converge on.
| Aspect | Recommendation |
|---|---|
| Frequency | Once daily (300 mg) or split twice daily (150 mg AM + 150 mg PM) — daily consistency matters more than timing precision |
| Best time of day | Morning or midday with a meal; evening dosing is fine and may have a mild calming effect for some users. Bacopa is not stimulating. |
| Food | Always with food — bacosides are lipophilic and absorption improves with dietary fat. Empty stomach is the most common cause of GI side effects. |
| Form | Standardized extract capsule preferred (consistent bacoside dose); softgels with oil base may improve absorption; raw powder works but is bitter and dose-imprecise; whole-herb capsules without standardization are not recommended. |
| Standardization marker | Look for “50–55% bacosides” on the label, or one of the branded clinical extracts: CDRI-08 (the originator extract from India's Central Drug Research Institute) or BacoMind. Avoid unstandardized “whole herb” products. |
| Cycling | No cycling pharmacologically required — chronic daily use is the studied protocol. Some users cycle 8 weeks on / 2 weeks off to assess subjective benefit during washout. |
What does Bacopa monnieri stack with?
Bacopa pairs naturally with faster-acting cognitive interventions because it operates on a fundamentally different timescale. The acute supplements and peptides handle today; Bacopa handles the structural memory consolidation that builds over weeks. The three areas below cover the natural stacking categories.
With peptides
Bacopa pairs naturally with the Russian-origin cognitive peptide cluster. Semax (an ACTH(4-10) analog) modulates BDNF and neurotrophic signaling — acute focus and resilience effects within minutes to hours. Selank (a tuftsin analog) provides anxiolytic and mild nootropic effects via GABA modulation — also acute. Bacopa is the slow, structural arm: dendritic branching, antioxidant neuroprotection, acetylcholinesterase inhibition — effects that build over 8–12 weeks. The peptides handle the same-day cognitive lift; Bacopa handles the three-months-from-now memory consolidation. Mechanistically complementary, no known negative interactions. Introduce one variable at a time when starting a new stack so you can tell what's actually doing what.
With supplements
- Alpha-GPC — acute acetylcholine substrate for daily attention; Bacopa is the chronic memory-consolidation layer. Classic complementary cognitive pairing.
- Lion's Mane — NGF/BDNF stimulation on a similar weeks-to-months timescale. Different mechanism (neurotrophic) but compatible chronic-use pairing with Bacopa's synaptic remodeling.
- Phosphatidylserine — cortisol-blunting plus membrane support. Complements Bacopa's anxiolytic and neuroprotective arms.
- Rhodiola Rosea — adaptogenic stress modulation. Both shift the stress response over chronic use; consistent with the Calabrese 2008 anxiety findings.
- Caffeine + L-theanine — acute focus stack that pairs cleanly with Bacopa's chronic memory benefits. No mechanistic conflict.
With lifestyle
- Daily consistency. The chronic-effect mechanism only works if you actually take it every day. Pair with an existing daily habit (morning coffee, breakfast) to anchor adherence.
- Take with fat-containing meal. Bacosides are lipophilic — a meal with some fat improves bioavailability and reduces GI side effects in one move.
- Time-boxed expectations. Plan to evaluate Bacopa at the 12-week mark, not the 2-week mark. Set a calendar reminder. Bacopa fails most often because users stop before the effect appears.
- Learning windows. The Roodenrys 2002 effect is specifically on retention of newly learned material. If you're studying or training intensively, Bacopa is well-matched to that use case — the consolidation benefit is exactly what learning relies on.
Side effects and interactions
Bacopa is well-tolerated in published trials. The dominant cluster of side effects is GI — nausea, cramping, loose stools — concentrated in users who take it on an empty stomach. Most other adverse effects are mild and dose-related.
Common (mostly transient)
- GI discomfort — nausea, cramping, loose stools or diarrhea, especially on empty stomach. Resolves with food, dose reduction, or split dosing.
- Dry mouth — mild and inconsistent; reported in some users.
- Mild fatigue or sedation — particularly at higher doses (600 mg) or in sensitive users. Reflects Bacopa's mild anxiolytic / GABAergic component.
- Increased gastric motility — bacosides have mild cholinergic effects on smooth muscle.
Less common (watch-list)
- Bradycardia (slow heart rate) — Calabrese 2008 documented a modest heart-rate reduction in the Bacopa group. Clinically irrelevant for most users but worth noting for users with pre-existing bradycardia.
- Mild thyroid hormone elevation — animal data suggests Bacopa can raise T4; human relevance unclear. Watch if you're on thyroid medication.
- Vivid dreams — occasionally reported; likely linked to serotonergic modulation.
Drug and supplement interactions
- Thyroid medications (levothyroxine, etc.) — Bacopa may modestly elevate T4 in animal models. Coordinate with the prescribing clinician if you're on thyroid replacement.
- Anticholinergic medications (some antihistamines, tricyclic antidepressants, bladder medications) — Bacopa's acetylcholinesterase inhibition may partially oppose these drugs. Consult a clinician if you're on chronic anticholinergic therapy.
- Cholinesterase inhibitors (donepezil, rivastigmine — Alzheimer's drugs) — additive cholinergic effect. Coordinate with the prescribing clinician.
- Sedatives (benzodiazepines, alcohol) — additive mild sedation possible at higher Bacopa doses. Not a contraindication but worth monitoring.
- Pregnancy and breastfeeding — insufficient data; avoid. Traditional Ayurvedic use does not constitute safety evidence for modern clinical recommendations.
How should Bacopa monnieri be stored?
Bacosides are sensitive to heat, light, and humidity. Standardized extract capsules are reasonably stable in normal household storage, but the active content degrades faster than most supplements when exposed to heat or sunlight. Powdered Bacopa is more sensitive than encapsulated forms.
- Capsules and softgels: store at room temperature in the original sealed container, away from direct sunlight. Once opened, use within 12 months. Avoid bathroom and kitchen storage — those are the highest-heat-and-humidity rooms in most homes.
- Powder: transfer to an airtight opaque container immediately on opening. Powdered Bacopa is more vulnerable to oxidation than the encapsulated form. Avoid clear-jar storage on a sunny shelf.
- Do not store above 25°C / 77°F for extended periods. Bacoside content degrades faster at higher temperatures — a hot car or a kitchen near the oven is the worst-case storage environment.
- Refrigeration is not required but doesn't hurt in hot or humid climates. If you do refrigerate, keep the container sealed to prevent condensation when warming to room temperature.
- Shelf life: typically 18–24 months from manufacture when sealed; 12 months after opening. Check the manufacture date when buying — Bacopa sitting on a warehouse shelf for 18+ months before purchase will have lower bacoside content than fresh stock.
What we don't know yet about Bacopa monnieri
Bacopa has one of the deeper traditional-herb RCT bases in the cognitive supplement literature, but several questions remain open — particularly around long-term safety in healthy populations, ADHD application validity, and the gap between the Indian and Western trial cohorts.
Long-term safety beyond 12 weeks. Nearly all RCT data is from 8–12 week trials. Multi-year daily use in healthy users is not characterized in controlled trials. The current best inference is that chronic daily 300 mg/day appears safe based on tolerability and traditional use, but the long horizon is genuinely unstudied in modern RCT format.
Healthy young-adult cognitive transfer. Most positive cognitive evidence comes from older adults (Calabrese 2008) or mixed middle-aged cohorts (Stough 2001, Roodenrys 2002). The case for healthy young adults (under 30) wanting cognitive enhancement is mechanistically reasonable but less directly supported by trial data.
ADHD evidence base. A small set of Indian RCTs in pediatric ADHD shows promising results, but the evidence has not been replicated outside India and the methodology in some of these trials is weaker than Western standards. Treat ADHD as a plausible application rather than an established one.
Branded-extract vs commodity-extract equivalence. CDRI-08 and BacoMind have specific clinical-trial data; the assumption that a generic 50% bacoside extract delivers equivalent outcomes is mechanistically plausible but not rigorously tested head-to-head. The branded extracts have a stronger evidence base; commodity extracts are reasonable but not RCT-validated as such.
Where studies disagree. The Kongkeaw 2014 meta-analysis found moderate heterogeneity across trials. Working memory and acute attention effects are inconsistent — some trials show benefit, others show null effects. The reliable signal is on delayed recall and consolidation; the unreliable signal is on working memory and acute processing.
Thyroid signal. Animal data suggests Bacopa can modestly elevate T4. The clinical relevance in humans is unstudied. For most users, this is a non-issue; for users on thyroid medication or with thyroid dysfunction, it's a watch-list item without clear guidance.
Where to buy Bacopa monnieri
Bacopa is available over-the-counter worldwide. Quality varies significantly — particularly around bacoside standardization disclosure, the gap between “whole herb” and standardized-extract products, and the branded-vs-commodity-extract question. The quality markers below are the screen we use before clicking through to a retailer.
Quality markers to look for
- 50–55% bacoside standardization on the label — this is the RCT-matched concentration. Avoid unstandardized “whole herb” products.
- CDRI-08 or BacoMind branded extract — the two extracts with direct clinical-trial data. Higher-confidence option for users who want the exact RCT-matched form.
- Latin binomial on the label (Bacopa monnieri) — “Brahmi” alone can refer to a different herb (Centella asiatica) in some traditions.
- Third-party tested — USP, NSF, or ConsumerLab certifications signal independent verification.
- Capsule form preferred over raw powder (bitter, dose-imprecise) or undefined tinctures. Softgels with oil base may improve absorption.
- No proprietary blends that obscure the actual Bacopa dose alongside other herbs or fillers.
- Fresh manufacture date — bacosides degrade with time; avoid jars sitting on warehouse shelves >18 months pre-purchase.
Amazon affiliate link — Prof. Peptide earns a small commission on qualifying purchases at no extra cost to you. We use commissions to fund research and editorial work.
Bacopa monnieri FAQ
Why does Bacopa take 8–12 weeks to do anything?
Because the cognitive benefits are structural, not acute. Bacosides A and B enhance dendritic branching and synaptic protein synthesis in hippocampal neurons — that's a slow remodeling process, not a fast neurotransmitter spike. Acute studies of a single Bacopa dose typically show no measurable cognitive effect; chronic studies at 8–12 weeks consistently show memory and processing-speed improvements. If you're three weeks in and feeling nothing, that's expected. If you want a same-day cognitive lift, Bacopa is the wrong supplement — Alpha-GPC, caffeine + L-theanine, or a racetam stack is what you want for acute effects.
What's the difference between CDRI-08, BacoMind, and generic 50% bacosides?
CDRI-08 is the originator standardized extract developed by India's Central Drug Research Institute — characterized at 55% bacosides via HPLC with a defined bacoside profile, and the extract used in several of the Stough and Roodenrys RCTs. BacoMind is a separately patented extract from Natural Remedies (India), also clinically studied, with a documented multi-bacoside profile (bacosides A1, A2, A3 and bacopasides). Generic "50% bacosides" is commodity-grade Bacopa standardized to total bacoside content but without the defined sub-fraction profile of the branded extracts. For most users, a reputable 50–55% bacoside extract from a quality manufacturer is fine; CDRI-08 or BacoMind is the higher-evidence choice if you want the exact RCT-matched extract.
Can I take Bacopa long-term? Should I cycle?
Long-term daily use is the model the published evidence supports — 12-week and longer trials with no concerning safety signals. There's no pharmacological reason to cycle Bacopa the way you'd cycle a stimulant; the mechanism is cumulative neural remodeling, not receptor downregulation. That said, some experienced users cycle 8 weeks on / 2 weeks off to assess subjective benefit (Bacopa's effects are subtle enough that a washout helps you tell whether it's still doing something). If you stop, the cognitive benefits fade over weeks — Bacopa is a maintenance tool, not a one-shot intervention.
Why does Bacopa upset my stomach?
Bacopa is mildly cholinergic and can stimulate gastric motility — common side effects are nausea, cramping, and loose stools, especially when taken on an empty stomach. The fix is straightforward: always take Bacopa with food, ideally a meal containing some fat (bacosides are lipophilic and absorption improves with dietary fat). If GI effects persist on a full stomach, lower the dose and titrate up over 1–2 weeks. Capsules tend to be better tolerated than raw powder. If you still can't tolerate it, that's the body telling you Bacopa isn't your supplement — there's no workaround.
Is Brahmi the same as Bacopa monnieri?
Usually, but not always — this is a real labeling problem. In most modern usage, "Brahmi" refers to Bacopa monnieri. But in some Ayurvedic traditions, "Brahmi" refers to Centella asiatica (gotu kola) — a completely different herb with different actives and different effects. Reputable Bacopa products list both names ("Bacopa monnieri / Brahmi") and specify the bacoside standardization. If a product is labeled only "Brahmi" with no Latin name or bacoside percentage, you can't be sure what you're buying. Always confirm the Latin binomial — Bacopa monnieri — and a bacoside-percentage standardization.
Can I stack Bacopa with Semax or Selank?
Yes — the stack is mechanistically natural and addresses different layers of cognitive function. Semax (an ACTH(4-10) analog) acutely modulates BDNF and neurotrophic signaling — fast-onset effects on focus and resilience. Selank (a tuftsin analog) provides anxiolytic and mild nootropic effects via GABA modulation — also acute. Bacopa is the chronic, structural arm: dendritic branching, antioxidant neuroprotection, acetylcholinesterase inhibition — effects that build over 8–12 weeks. The peptides handle today; Bacopa handles three months from now. No known negative interactions, but introduce one variable at a time so you can tell what's actually doing what.
Does Bacopa work for anxiety or ADHD?
Anxiety: yes, with reasonable evidence. Calabrese 2008 (RCT in older adults) documented significant anxiety and depression reductions with chronic Bacopa supplementation. The mechanism is partly serotonergic and partly cortisol-modulating — an anxiolytic effect that builds gradually rather than acutely. ADHD: weaker evidence. A 2014 Indian RCT in children with ADHD suggested cognitive and attention improvements with Bacopa, but the trial base is small, mostly from one research group, and not replicated in Western populations. Treat the ADHD application as plausible but not established; the anxiety application has stronger support.
How does Bacopa compare to Alpha-GPC or Lion's Mane?
Different timescales, different mechanisms, often stacked together. Alpha-GPC is the acetylcholine substrate — fast-acting, daily attention and reaction-time effects, evidence in dementia and acute exercise GH. Lion's Mane works through NGF/BDNF stimulation — also chronic, weeks-to-months timescale, evidence in mild cognitive impairment and nerve recovery. Bacopa is the memory-consolidation and anxiolytic arm — chronic, 8–12 weeks, evidence in healthy-adult memory and anxiety RCTs. The three are mechanistically distinct enough that stacking is rational; many users run all three as a daily cognitive baseline.
References
- Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology. 2001;156(4):481-484. https://pubmed.ncbi.nlm.nih.gov/11498727/
- Roodenrys S, Booth D, Bulzomi S, et al. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279-281. https://pubmed.ncbi.nlm.nih.gov/12093601/
- Calabrese C, Gregory WL, Leo M, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707-713. https://pubmed.ncbi.nlm.nih.gov/18611150/
- Stough C, Downey LA, Lloyd J, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629-1634. https://pubmed.ncbi.nlm.nih.gov/18683852/
- Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528-535. https://pubmed.ncbi.nlm.nih.gov/24252493/
- Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med. 2010;16(7):753-759. https://pubmed.ncbi.nlm.nih.gov/20590480/
Published Studies
Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.
Stough C, Lloyd J, Clarke J, et al.
A 12-week randomized double-blind placebo-controlled trial of 300 mg/day Bacopa extract in 46 healthy adults. Bacopa supplementation significantly improved speed of information processing, learning rate, and memory consolidation versus placebo. The cognitive gains emerged after the 5-week mark and were maximal at 12 weeks — establishing the chronic-effect timeline that subsequent Bacopa research has confirmed. One of the foundational Western RCTs that moved Bacopa from "traditional Ayurvedic herb" to "clinically supported nootropic" in the cognitive supplement literature.
Roodenrys S, Booth D, Bulzomi S, et al.
A 12-week randomized double-blind placebo-controlled trial of Bacopa extract in 76 adults aged 40–65. Bacopa produced a significant effect on retention of new information — specifically reducing the rate of forgetting newly learned material in the Auditory Verbal Learning Test (AVLT). Working memory and short-term retrieval were not significantly affected. The Roodenrys trial is methodologically clean and establishes that Bacopa's memory benefit is specifically a consolidation/retention effect, not a working-memory or acute-attention effect — useful for setting realistic expectations.
Calabrese C, Gregory WL, Leo M, et al.
A 12-week RCT of 300 mg/day standardized Bacopa extract in 54 community-dwelling participants aged 65 and older. Bacopa significantly improved AVLT delayed word recall, Stroop test performance, and reduced depression and anxiety scale scores versus placebo. Heart rate decreased modestly in the Bacopa group. The trial extended Bacopa's evidence base into the older-adult population and provides the cleanest published evidence for Bacopa's combined cognitive + anxiolytic effects in a single trial.
Stough C, Downey LA, Lloyd J, et al.
A 90-day RCT of 300 mg/day Bacopa (BacoMind extract) in 62 healthy adults aged 18–60. Bacopa significantly improved spatial working memory, rapid visual information processing, and reduced state anxiety versus placebo. The trial is one of several from the Stough group at Swinburne University that collectively form the largest single-lab body of Bacopa cognitive evidence. The 90-day duration confirms the chronic-effect timeline; the BacoMind extract is one of the two main branded standardized extracts with clinical-trial support.
Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, et al.
A systematic review and meta-analysis of nine double-blind placebo-controlled RCTs of Bacopa monnieri (n=437 total participants). The meta-analysis found Bacopa significantly improved cognitive performance, particularly in tests of attention, cognitive processing, and choice reaction time. Memory improvements were significant for delayed word recall and free recall but inconsistent for working memory. Heterogeneity across trials was moderate. The Kongkeaw meta-analysis is the most-cited quantitative synthesis of Bacopa's cognitive evidence and the reference document for the "strong evidence base" claim in the supplement literature.
Related Supplements
We may earn commissions from peptide vendor affiliate links.
Have a question about Bacopa Monnieri? Send us an email →